Slide 1. First three months of 2018 Conference call
|
|
- Garry Tate
- 5 years ago
- Views:
Transcription
1 Slide First three months of 208 Conference call Manato Shirley Ohara, Adelia Stewart diagnosed has type with 2 diabetes type diabetes Kanagawa, New Orleans, Japan Louisiana, US
2 Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook
3 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation as well as the company s statutory Annual Report 207 and Form 20-F, which are both filed with the SEC in ruary 208 in continuation of the publication of the Annual Report 207, and written information released, or oral statements made, to the public in the future by or on behalf of Novo Nordisk, may contain forward-looking statements. Words such as believe, expect, may, will, plan, strategy, prospect, foresee, estimate, project, anticipate, can, intend, target and other words and terms of similar meaning in connection with any discussion of future operating or financial performance identify forward-looking statements. Examples of such forward-looking statements include, but are not limited to: Statements of targets, plans, objectives or goals for future operations, including those related to Novo Nordisk s products, product research, product development, product introductions and product approvals as well as cooperation in relation thereto, Statements containing projections of or targets for revenues, costs, income (or loss), earnings per share, capital expenditures, dividends, capital structure, net financials and other financial measures, Statements regarding future economic performance, future actions and outcome of contingencies such as legal proceedings, and Statements regarding the assumptions underlying or relating to such statements. These statements are based on current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. Novo Nordisk cautions that a number of important factors, including those described in this presentation, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results include, but are not limited to, global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations, delay or failure of projects related to research and/or development, unplanned loss of patents, interruptions of supplies and production, product recalls, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Novo Nordisk s products, introduction of competing products, reliance on information technology, Novo Nordisk s ability to successfully market current and new products, exposure to product liability and legal proceedings and investigations, changes in governmental laws and related interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing and marketing, perceived or actual failure to adhere to ethical marketing practices, investments in and divestitures of domestic and foreign companies, unexpected growth in costs and expenses, failure to recruit and retain the right employees, and failure to maintain a culture of compliance. For an overview of some, but not all, of the risks that could adversely affect our results or the accuracy of forward-looking statements in this presentation, reference is made to the overview of risk factors in The Risks of Doing Business on pp of the Annual Report 207. Unless required by law, Novo Nordisk is under no duty and undertakes no obligation to update or revise any forward-looking statement after the distribution of this presentation, whether as a result of new information, future events or otherwise. Important drug information Victoza (liraglutide.2 mg &.8 mg) is approved for the management of type 2 diabetes only Saxenda (liraglutide 3 mg) is approved in the US and EU for the treatment of obesity only
4 Slide 4 Highlights First three months of 208 Sales development Sales decreased by 5% in Danish kroner and increased by 5% in local currencies to DKK 26.9 billion International Operations sales were flat in Danish kroner and grew by 8% in local currencies Region Latin America sales increased by 44% in Danish kroner and increased by 73% in local currencies Region AAMEO sales declined by 2% in Danish kroner and grew by 2% in local currencies Region China declined by % in Danish kroner and grew by 6% in local currencies North America Operations sales decreased by % in Danish kroner and increased by 3% local currencies Victoza and Tresiba accounted for the largest share of growth and grew by 8% and 33% in local currencies, respectively Research and Development Ozempic granted marketing authorisation by the European Commission and approved in Japan Successful completion of the first phase 3a trial, PIONEER, with oral semaglutide Tresiba label in the USA updated to include cardiovascular safety data and 40% reduction of severe hypoglycaemic events compared to insulin glargine U00 Financials Operating profit decreased by 8% in Danish kroner and increased by 6% in local currencies to DKK 2.4 billion Net profit increased by 6% to DKK 0.8 billion Diluted earnings per share increased by 8% to 4.40 DKK per share 208 financial outlook: Sales growth is now expected to be 3-5% measured in local currencies (now around 6% lower reported) Operating profit growth is now expected to be 2-5% measured in local currencies (now around 9% lower reported)
5 Slide 5 Sales growth driven by both International Operations and North America Operations Sales as reported first quarter of 208 Region AAMEO (2%) Region Japan & Korea (4%) Region China (%) Region Europe 0% % % Region Latin America +44% 4% 5% 9% 50% Sales of DKK 26.9 billion (5%) North America Operations (%) Growth break down first quarter of 208 Local currencies Growth Share of growth North America Operations 3% 30% Hereof USA 3% 30% International Operations 8% 70% Region Europe % 2% Region AAMEO 2% 23% Region China 6% 2% Region Japan & Korea (6%) (6%) Region Latin America 73% 39% Total sales 5% 00% AAMEO: Africa, Asia, Middle East & Oceania
6 Slide 6 Sales growth in local currencies of 5% mainly driven by Victoza and Saxenda Sales as reported first quarter of 208 Growth break down first quarter of 208 Haemophilia (3%) Obesity +43% Growth hormone (0%) 7% 6% 9% 2% % Other biopharmaceuticals (28%) 3% 2% 79% 8% Sales of DKK 26.9 billion (5%) Diabetes care (6%) Local currencies Growth Share of growth Long-acting insulin (3%) (0%) Premix insulin 2 % 2% Fast-acting insulin 3 0% 0% Human insulin 3% 4% GLP- 4 9% 73% Other diabetes care 5 5% 4% Total diabetes care 5% 73% Obesity (Saxenda ) 64% 23% Diabetes care and obesity total 6% 96% Haemophilia 6 7% 2% Growth disorders 0% 0% Other biopharmaceuticals 7 (23%) (8%) Biopharmaceuticals % 4% Total 5% 00% Comprises Tresiba, Xultophy and Levemir ; 2 Comprises Ryzodeg and NovoMix 3 Comprises Fiasp and NovoRapid ; 4 Comprises Ozempic and Victoza 5 Primarily NovoNorm and needles; 6 Comprises NovoSeven, NovoEight, NovoThirteen and Refixia ; 7 Primarily Vagifem and Activelle
7 Slide 7 Novo Nordisk aims for leadership in long-acting insulin and sustained leadership for fast-acting and premix insulin Long-acting insulin volume market share across regions 80% 70% 60% 50% 40% 30% 20% 0% 0% 203 Novo Nordisk Region China 208 Fast-acting insulin 2 volume market share across regions North America Operations Region Japan & Korea 80% 70% 60% 50% 40% 30% 20% 0% 0% Long-acting insulin comprises: Tresiba, Levemir, Xultophy and Insulatard (basal human insulin). Please note that not all products are launched in all markets 2 Short-acting insulin includes: Fiasp, NovoLog and Mixtard 30 (premix human insulin). Please note that not all products are launched in all markets 3 Premix insulin includes: Ryzodeg, NovoMix and Actrapid (bolus human insulin). Please note that not all products are launched in all markets Premix insulin 3 volume market share across regions Region Europe Region Latin America 80% 70% 60% 50% 40% 30% 20% 0% 0% 203 Region AAMEO 208
8 Slide 8 Novo Nordisk holds ~35% volume market share of the basal market in the USA Weekly TRx volume market shares in the USA glargine U00 Basal volume TRx MS 70% 60% 50% 40% 30% 20% 0% 0% Mar 206 NN Total Basal Levemir Tresiba glargine U300 biosimilar glargine U00 Mar 208 Note: The graph does not show NPH, which accounts for the residual market share Source: IQVIA weekly Xponent Plantrak, 23 March 208 Excludes Medicaid that represents ~2% of retail basal market volume and basal insulin and GLP- combination products such as Xultophy TRx volume: Insulin volume in mega units (MU) associated with total number of prescriptions; MS: Market share 42.2% 34.8% 22.8%.8% 8.5% 8.4% Tresiba launch in the USA Tresiba TRx volume market share is now.8% Main market share driver in Q 208 has been the formulary change at CVS part D Tresiba formulary access is now estimated to be around 80% 2 for Commercial and Medicare Part D combined, following formulary access on United Health Care Part D Tresiba label in the USA updated to include cardiovascular safety data and 40% reduction of severe hypoglycaemic events compared to insulin glargine U00. The updated Tresiba label was launched mid-april 208 in the USA Source: IQVIA weekly Xponent Plantrak, 23 March, 208 CVS formulary Silverscript 2 Projected access calculated from VANTAGE FingerTip Formulary bridge ruary 208, week ending 2 March 208.
9 Slide 9 Victoza sales growth of 20% in the USA driven by GLP- market volume growth of ~23% USA GLP- market development MAT GLP- TRx volume (million) Total TRx Growth rate MAT volume growth rate % 30% 25% 20% 5% 0% 5% 0% USA GLP- market monthly TRx GLP- TRx volume (thousand) NN GLP- Victoza Ozempic dulaglutide exenatide albiglutide 208 USA GLP- volume market share GLP- TRx market share 00% 80% 60% 40% 20% 0% 205 NN GLP- Victoza Ozempic dulaglutide exenatide albiglutide 44% 37% 5% 4% 208 Source: IQVIA NPA monthly, 208
10 Slide 0 First phase 3a trial with oral semaglutide, PIONEER, in adults with type 2 diabetes completed Reduction in HbA c with oral semaglutide, administered once daily as a tablet vs placebo Reduction in body weight with oral semaglutide, administered once daily as a tablet vs placebo HbA c reduction (%) Oral sema 3 mg 0.0 Oral sema 7 mg Oral sema 4 mg Placebo Weight loss (kg) 0.0 Oral sema 3 mg Oral sema 7 mg Oral sema 4 mg Placebo % % kg -2.5 kg -.5 kg % -.5% kg Results illustrated by using the secondary statistical method called hypothetical estimand: Treatment effect, if all participants followed the treatment without rescue medication (analysed by using Mixed Models for Repeated Measurements (MMRM)). The statistical method is consistent with e.g. the statistical method used for the SUSTAIN programme for subcutaneous semaglutide. Sema: Semaglutide
11 Slide All 0 PIONEER trials for oral semaglutide expected to read-out during PIONEER : monotherapy 2 26 weeks, n=704 PIONEER 2: vs empagliflozin 2 52 weeks, n=86 PIONEER 3: vs sitagliptin 2 78 weeks, n=,860 PIONEER 4: vs liraglutide 2 52 weeks, n=690 PIONEER 5: moderate renal impairment 2 26 weeks, n=324 PIONEER 6: cardiovascular outcomes 3 Event driven (>22 MACE), n=3,76 PIONEER 7: flexible dose escalation 4 52 weeks, n=500 PIONEER 8: insulin add-on weeks, n=720 PIONEER 9: JAPAN monotherapy 2 52 weeks, n=230 PIONEER 0: JAPAN OAD combination 4 52 weeks, n=336 Q 208 Q2 208 Q3 208 Q weeks extension trial Expected to be published in the given quarter or in the subsequent quarterly company announcement. Estimated timing from first patient first visit to completion of trial 2 Primary endpoint after 26 weeks of treatment by using the statistical method: Treatment policy estimand approach 3 Primary endpoint after >22 major adverse cardiovascular events (MACE), defined by non-fatal stroke, non-fatal myocardial infarction or CV death 4 Primary endpoint after 52 weeks of treatment by using the statistical method: Treatment policy estimand approach Note: n = approximate number of randomised people; OAD: oral anti-diabetic
12 Slide 2 Tresiba label in the USA updated based on DEVOTE trial data Lower rates of severe hypoglycaemia demonstrated in DEVOTE trial FDA approved a label update for Tresiba for people with type 2 diabetes glargine U00 Tresiba Food and Drug Administration (FDA) approved updates to the US prescribing information for Tresiba to include data -40% * from the DEVOTE trial including: % * Cardiovascular safety based on Tresiba demonstrated non-inferiority compared to insulin glargine U00 with regards to major adverse cardiovascular events (MACE) with a hazard ratio of Statistically significant 40% reduction of severe hypoglycaemic events compared to insulin glargine U00 Subjects with one or more severe events Number of overall severe events The supplemental applications to include the two SWITCH trials have been withdrawn following interactions with FDA * Statistically significant Source: Marso et al. New England Journal of Medicine 207;377: MACE defined as first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke
13 Slide 3 Key development milestones Ozempic granted marketing authorisation by European Commission and approved in Japan Variation applications for Ozempic submitted to the EMA for the devices and inclusion of SUSTAIN 7 data New drug application for Ryzodeg submitted to the China FDA Diabetes Xultophy label to include LEADER and DEVOTE data submitted to the FDA and positive opinion adopted by CHMP in the EU DUAL I Japan phase 3a trial with Xultophy completed LAI287 phase trials completed and phase 2 initiation expected before end of 208 Development of PI406 to be discontinued following phase results HypoPen 53 initiated in phase Obesity Biopharm AM833 phase results completed and phase 2 initiation expected early 209 N8-GP submitted for regulatory approval in the USA and the EU for treatment of haemophilia A Phase /2 multiple dose trial with subcutaneous N8-GP initiated following completion of single dose trial Worldwide license to EpiDestiny s sickle cell disease programme (EPI0) obtained Norditropin label in the USA updated with two additional indications
14 Slide 4 R&D milestones in 208 Results available Regulatory milestone Project Q 208 Q2 208 Q3 208 Q4 208 Tresiba Xultophy DEVOTE and SWITCH 2 US regulatory decision DUAL I Japan Phase 3a DUAL II Japan Phase 3a Japan submission Fiasp Japan submission Ozempic Oral semaglutide LAI287 AM833 N9-GP EU and Japan regulatory decision PIONEER data Phase data PIONEER 2, 3, 4 and 7 data Phase data PIONEER 5 and 0 data Japan regulatory decision PIONEER 6, 8 and 9 data N8-GP US/EU submission Japan submission Concizumab explorer 5 data explorer 4 data EU variation applications Somapacitan REAL 3 Phase 2, GHD data REAL (extension) Phase 3, AGHD data Diabetes Obesity Haemophilia Growth disorders Expected to be published in the given quarter or in the subsequent quarterly company announcement 2 Supplemental applications to include the two SWITCH trials have been withdrawn based on interactions with FDA GHD: Growth hormone deficiency; AGHD: Adult growth hormone deficiency Note: G530L has been removed from the overview as the project is still being evaluated in phase Note: Tresiba vs insulin glargine U300 trial has been postponed and is no longer expected to read-out in Q4 208
15 Slide 5 Financial results First three months of 208 DKK million Q 208 Q 207 Change (reported DKK) Change (local currency) Sales 26,930 28,452 (5%) 5% Gross profit 22,733 24,20 (6%) Gross margin 84.4% 85.% Sales and distribution costs (6,45) (6,787) (5%) 5% Percentage of sales 24.0% 23.9% Research and development costs (3,32) (3,289) % 5% Percentage of sales 2.3%.6% Administration costs (864) (93) (5%) 0% Percentage of sales 3.2% 3.2% Other operating income, net % Operating profit 2,448 3,490 (8%) 6% Operating margin 46.2% 47.4% Financial items (net),6 (486) Profit before income tax 3,609 3,004 5% Income taxes (2,858) (2,848) 0% Effective tax rate 2.0% 2.9% Net profit 0,75 0,56 6% Diluted earnings per share (DKK) %
16 Non-hedged currencies Index ( Jan 207 = 00) Hedged currencies Index ( Jan 207= 00) Conference call First three months of 208 Slide 6 Unfavourable currency impact in Q 208 driven by development in both hedged and unhedged currencies USD/DKK RUB/DKK CNY/DKK INR/DKK JPY/DKK ARS/DKK GBP/DKK BRL/DKK CAD/DKK TRY/DKK Hedged 207 Currencies average Non-hedged 207 Currencies average 208 average average 2 Spot rate 2 Spot rate 2 ARS TRY INR RUB BRL Impact of a 5% move 3 DKK per 00; 2 As of 25 April 208; 3 Impact on operating profit in the next 2 months of a 5% immediate currency move. DKK million per annum; 4 Chinese Yuan traded offshore (CNH) Note: Operating profit impact of one of the non-hedged currencies appreciating 5% is in the range of DKK -5 to +50 million Hedging (months) USD ,900 2 CNY JPY GBP CAD
17 Slide 7 Financial outlook for 208 Sales growth - local currencies Expectations 2 May 208 3% to 5% Previous expectations 208 2% to 5% Sales growth - reported Operating profit growth - local currencies Operating profit growth - reported Financial items (net) Effective tax rate Capital expenditure Depreciation, amortisation and impairment losses Free cash flow Around 6 percentage point lower 2% to 5% Around 9 percentage point lower Gain of around DKK.9 billion 20% to 22% Around DKK 9.5 billion Around DKK 3 billion Around DKK 27 to 32 billion Around 7 percentage points lower % to 5% Around 0 percentage points lower Gain of around DKK 2.5 billion 20% to 22% Around DKK 9.5 billion Around DKK 3 billion Around DKK 27 to 32 billion The financial outlook is based on an assumption of a continuation of the current business environment and given the current scope of business activities and has been prepared assuming that currency exchange rates remain at the level as of 25 April 208
18 Slide 8 Closing remarks Solid leadership positions and continued market opportunities Promising pipeline and product launches 27% Novo Nordisk value market share in diabetes > The only company with a full portfolio of novel care and solid leadership position insulin and GLP- products ~5% insulin market volume growth 45% Novo Nordisk insulin volume market share with leadership position across all regions >2% GLP- volume market growth 54% Novo Nordisk GLP- volume market share with global leadership position 38% Saxenda value market share with a global leadership in the anti obesity market Semaglutide portfolio offers expansion opportunity with both once-weekly Ozempic and oral administration Xultophy supports promising outlook for insulin and GLP- combination therapy Saxenda and multiple clinical stage development projects hold potential within obesity Broad pipeline within haemophilia Source: IQVIA MAT 208 volume and value (DKK) figures
19 Slide 9 Investor contact information Share information Novo Nordisk s B shares are listed on the stock exchange in Copenhagen under the symbol NOVO B. Its ADRs are listed on the New York Stock Exchange under the symbol NVO. For further company information, visit Novo Nordisk on the internet at: novonordisk.com Upcoming events 24 Jun 208 American Diabetes Association investor presentation 08 Aug 208 Financial statement for the first six months of 208 Investor Relations contacts Novo Nordisk A/S Investor Relations Novo Allé, DK-2880 Bagsværd Peter Hugreffe Ankersen phak@novonordisk.com Anders Mikkelsen armk@novonordisk.com Christina Kjær cnje@novonordisk.com 0 Nov 208 Financial statement for the first nine months of Financial statement for 208
Slide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationSlide 1. First six months of London 10 August Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan
Slide 1 First six months of 2017 London 10 August 2017 Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook
More informationSlide 1. Investor Presentaton Jefferies Global Healthcare Conference. New York, 7 June Shanghai part of Cities Changing Diabetes
Slide 1 Investor Presentaton Jefferies Global Healthcare Conference New York, 7 June 2016 Shanghai part of Cities Changing Diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationBusiness update InvestorDagen
Slide 1 Business update 28 November 2017 Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities
More informationSlide 1. First nine months of London 2 November Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan
Slide 1 First nine months of 2017 London 2 November 2017 Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook
More informationSlide 1. Full year London 5 February Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan
Slide 1 Full year 2017 London 5 February 2018 Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide
More informationSlide 1. Conference call Full year 2018
Slide Conference call Full year 208 Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationInvestor conference call First quarter of 2016
Slide 1 Investor conference call First quarter of 2016 Shanghai part of Cities Changing Diabetes Slide 2 Agenda Highlights and key events By Lars Rebien Sørensen, president and CEO Sales update By Lars
More informationSlide 1. Jefferies 2014 Global Healthcare Conference 5-June Karsten Munk Knudsen CVP of Finance & IT at NNI
Slide 1 Jefferies 2014 Global Healthcare Conference 5-June-2014 Karsten Munk Knudsen CVP of Finance & IT at NNI Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide
More informationSlide 1. Investor presentation Full year London, 4 February Shanghai part of Cities Changing Diabetes
Slide 1 Investor presentation Full year 2015 London, 4 February 2016 Shanghai part of Cities Changing Diabetes Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide
More informationSlide 1. Investor presentation. Copenhagen 1 November 2018
Slide 1 Investor presentation Copenhagen 1 November 2018 Manato Shirley Ohara, Adelia Stewart diagnosed has type with 2 diabetes type 1 diabetes Kanagawa, New Orleans, Japan Louisiana, US Slide 2 Highlights
More informationSlide 1. Winning with GLP-1. Lars Fruergaard Jørgensen President and CEO. ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes
Slide 1 Lars Fruergaard Jørgensen President and CEO ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the
More informationSlide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO
Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission
More informationOral semaglutide and production expansion. Henrik Wulff EVP Product Supply. Peter Kristensen SVP Global Development
YASMIN FIEDLER Germany Yasmin has type 1 diabetes Slide 1 Oral semaglutide and production expansion Henrik Wulff EVP Product Supply Peter Kristensen SVP Global Development Slide 2 Forward-looking statements
More informationSlide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO
Slide 1 Lars Fruergaard Jørgensen President and CEO Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the company
More informationInternational Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1
Slide 1 International Operations overview and strategy Maziar Mike Doustdar EVP International Operations KUALA LUMPUR Home of International Operations Business Area Southeast Asia Slide 2 Forward-looking
More informationNovo Nordisk's operating profit decreased by 8% in Danish kroner and increased by 4% in local currencies in the first six months of 2018
report for the period 1 January 2018 to 30 June 2018 8 August 2018 Novo Nordisk's operating profit decreased by 8% in Danish kroner and increased by 4% in local currencies in the first six months of 2018
More informationSlide 1. Investor presentation First nine months of 2018
Slide Investor presentation First nine months of Manato Shirley Ohara, Adelia Stewart diagnosed has type with 2 diabetes type diabetes Kanagawa, New Orleans, Japan Louisiana, US Slide 2 Agenda Highlights
More informationFinancial report for the period 1 January 2017 to 30 September November Novo Nordisk A/S Investor Relations
report for the period 1 January 2017 to 30 September 2017 1 November 2017 Novo Nordisk increased reported operating profit by 5% in the first nine months of 2017 Reported sales increased by 2% to DKK 83.7
More informationNovo Nordisk increased reported operating profit by 8% in the first six months of 2017 Sales increased by 4% measured in Danish kroner
report for the period 1 January 2017 to 30 June 2017 9 August 2017 Novo Nordisk increased reported operating profit by 8% in the first six months of 2017 Sales increased by 4% measured in Danish kroner
More informationSlide 1. Investor presentation First three months of 2018
Slide Investor presentation First three months of 208 Manato Shirley Ohara, Adelia Stewart diagnosed has type with 2 diabetes type diabetes Kanagawa, New Orleans, Japan Louisiana, US Slide 2 Agenda Highlights
More informationNet profit increased by 1% to DKK 38.6 billion and diluted earnings per share increased by 4% to DKK
report for the period 1 January 2018 to 31 December 2018 1 February 2019 Novo Nordisk's operating profit decreased by 4% in Danish kroner and increased by 3% in local currencies in 2018 Operating profit
More informationSlide 1. First six months of Copenhagen 8 August 2018
Slide First six months of 208 Copenhagen 8 August 208 Manato Shirley Ohara, Adelia Stewart diagnosed has type with 2 diabetes type diabetes Kanagawa, New Orleans, Japan Louisiana, US Slide 2 Agenda Highlights
More informationSlide 1. Investor presentation. Meet the Management London, 9 August 2018
Slide 1 Investor presentation Meet the Management London, 9 August 2018 Manato diagnosed with type 1 diabetes Shirley Ohara, Adelia Stewart has type 2 diabetes Kanagawa, Japan New Orleans, Louisiana, US
More informationSlide 1. First nine months of Copenhagen 1 November Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan
Slide First nine months of 207 Copenhagen November 207 Manato Ohara, diagnosed with type diabetes Kanagawa, Japan Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook
More informationSlide 1. R&D strategy. Mads Krogsgaard Thomsen EVP and Chief Science Officer. ZIHAO LI AND HIS MOTHER BING HAN, China Zihao has haemophilia A
Slide 1 R&D strategy Mads Krogsgaard Thomsen EVP and Chief Science Officer ZIHAO LI AND HIS MOTHER BING HAN, China Zihao has haemophilia A R&D strategy Slide 2 Forward-looking statements Novo Nordisk s
More informationSlide 1. Investor presentation Full year 2018
Slide Investor presentation Full year 28 Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide 3 Forward-looking statements o Nordisk s reports filed with or furnished
More informationSlide 1. Full year Copenhagen 1 February Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan
Slide Full year 207 Copenhagen February 208 Manato Ohara, diagnosed with type diabetes Kanagawa, Japan Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide 3 Forward-looking
More informationMAGAZINE CAMILLA SYLVEST JOINS EXECUTIVE MANAGEMENT NEW INTERESTING RESULTS WITH SEMAGLUTIDE
MAGAZINE NO 3 217 QUARTERLY INVESTOR UPDATE CAMILLA SYLVEST JOINS EXECUTIVE MANAGEMENT NEW INTERESTING RESULTS WITH SEMAGLUTIDE VICTOZA APPROVED IN THE US AND THE EU AS THE ONLY GLP-1 PRODUCT TO PREVENT
More informationInvestor presentation First nine months of 2016
Slide Investor presentation First nine months of 26 Shanghai part of Cities Changing Diabetes Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide 3 Forward-looking
More informationSlide 1. Full year Copenhagen, 2 February Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan
Slide Full year 206 Copenhagen, 2 February 207 Manato Ohara, diagnosed with type diabetes Kanagawa, Japan Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide 3
More informationSlide 1. Investor presentation First half of Copenhagen, 5 August Shanghai part of Cities Changing Diabetes
Slide Investor presentation First half of 26 Copenhagen, 5 August 26 Shanghai part of Cities Changing Diabetes Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide
More informationNovo Nordisk increased operating profit by 15% in the first six months of 2013 Sales growth of 11% driven by Victoza, NovoRapid and Levemir
report for the period 1 January 2013 to 30 June 2013 8 August 2013 Novo Nordisk increased operating profit by 15% in the first six months of 2013 Sales growth of 11% driven by Victoza, NovoRapid and Levemir
More informationNovo-Nordisk As (NVO-NYSE) Analyst Note
February 03, 2015 Novo-Nordisk As (NVO-NYSE) Analyst Note NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 02/10/2014 Current Price (02/02/15) $44.73 Target Price $47.00
More informationInvestor presentation Full year 2016
Slide Investor presentation Full year 26 Manato Ohara, diagnosed with type diabetes Kanagawa, Japan Slide 2 Forward-looking statements o Nordisk s reports filed with or furnished to the US Securities and
More informationInvestor presentation First nine months of 2015
Slide Investor presentation First nine months of 25 Mexico City part of Cities Changing Diabetes Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide 3 Forward-looking
More informationFinancial statement for January Novo Nordisk A/S Investor Relations. Novo Allé 2880 Bagsværd Denmark
statement for 2012 31 January 2013 Novo Nordisk increased operating profit by 32% in 2012 Sales growth of 18% driven by Victoza, NovoRapid and Levemir Sales increased by 18% to 78.0 billion in Danish kroner
More informationshare SAXENDA LAUNCHED IN THE US FOR THE TREATMENT OF OBESITY POSITIVE TRIAL RESULTS FOR GLP-1 TABLET FIRST QUARTER: OPERATING PROFIT INCREASED BY 17%
share QUARTERLY INVESTOR UPDATE MAY 21 QUARTERLY INVESTOR UPDATE MAY 21 SAXENDA LAUNCHED IN THE US FOR THE TREATMENT OF OBESITY POSITIVE TRIAL RESULTS FOR GLP-1 TABLET FIRST QUARTER: OPERATING PROFIT INCREASED
More informationSlide 1. Investor presentation Full year Copenhagen, 3 February Shanghai part of Cities Changing Diabetes
Slide Investor presentation Full year 205 Copenhagen, 3 February 206 Shanghai part of Cities Changing Diabetes Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide
More informationAmerican Diabetes Association 76 th Scientific Sessions. Investor and analyst event. New Orleans, 13 June Slide 1
Slide 1 American Diabetes Association 76 th Scientific Sessions Investor and analyst event New Orleans, 13 June 216 Shanghai part of Cities Changing Diabetes Slide 2 Forward-looking statements Novo Nordisk
More informationNovo Nordisk increased operating profit by 18% in the first quarter of 2013 Sales growth of 13% driven by Victoza, NovoRapid and Levemir
report for the period 1 January 2013 to 31 March 2013 1 May 2013 Novo Nordisk increased operating profit by 18% in the first quarter of 2013 Sales growth of 13% driven by Victoza, NovoRapid and Levemir
More informationInvestor presentation Full year 2014
Slide Investor presentation Full year 24 Mexico City part of Cities Changing Diabetes Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide 3 Forward-looking statements
More informationANNUAL REPORT novo nordisk A NEW ERA OF DIABETES TREATMENT? DEFINING TIMES FOR THE US BUSINESS
novo nordisk ANNUAL REPORT 2016 Årsrapport for 2016 for Novo Nordisk A/S for perioden 1. januar til 31. december 2016 Godkendt på generalforsamlingen 23. marts 2016 Dirigent Klaus Søgaard Novo Allé, 2880
More informationMAGAZINE NOVO NORDISK RESEARCH CENTRE OPENS IN OXFORD PHASE 2 DATA FOR SOMAPACITAN DEMONSTRATE BIG POTENTIAL CONNECTED INSULIN PENS POISED FOR LAUNCH
MAGAZINE NO 3 218 QUARTERLY INVESTOR UPDATE NOVO NORDISK RESEARCH CENTRE OPENS IN OXFORD PHASE 2 DATA FOR SOMAPACITAN DEMONSTRATE BIG POTENTIAL CONNECTED INSULIN PENS POISED FOR LAUNCH NINE MONTHS OF SOLID
More informationNOVO NORDISK. Analyst: Recommendation: HOLD DATE: Industry: Drug manufacturers
NOVO NORDISK Analyst: Recommendation: HOLD DATE: 11.11.2015 Industry: Drug manufacturers Share price 375,00 DKK Homepage www.novonordisk.com Ticker NVO Number of shares (000) 2.563.800 Target price 406,14
More informationH. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011
H. LUNDBECK A/S Teleconference 10 August 2011-2PM CET Financial results Second quarter 2011 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts
More informationTELECONFERENCE FY February 2015
TELECONFERENCE FY 2014 5 February 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationNet profit increased by 13% to DKK 9,645 million. Earnings per share (diluted) increased by 16% to DKK
Company Announcement 29 January 2009 Novo Nordisk increased operating profit by 38% in 2008 Performance driven by sales of modern insulins and gross margin improvement. Dividend to be increased by 33%.
More informationTELECONFERENCE Q August 2015
TELECONFERENCE Q2 2015 19 August 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationTELECONFERENCE Q November 2015
TELECONFERENCE Q3 2015 4 November 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationNovo Nordisk has proposed to acquire Ablynx for up to per share in cash, consisting of upfront and 2.50 in Contingent Value Rights
Novo Nordisk has proposed to acquire Ablynx for up to 30.50 per share in cash, consisting of 28.00 upfront and 2.50 in Contingent Value Rights Proposal consists of upfront cash consideration of 28.00 per
More informationJEFFERIES 2016 HEALTHCARE CONFERENCE. June 2016
JEFFERIES 2016 HEALTHCARE CONFERENCE June 2016 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationEli Lilly and Company Investment Community Meeting
Eli Lilly and Company Investment Community Meeting October 3, 2013 8:30 a.m. 12:30 p.m. Safe Harbor Provision This presentation contains forward-looking statements that are based on management's current
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationDELICA D:5 ACTIVE GEAR 0
DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion
More informationInvestor Update May 2016
Investor Update May 2016 Novo Nordisk poised for growth through helping care for rising global diabetes epidemic On Marsico Capital Management s trip to Australia in March, Portfolio Managers Tom Marsico
More informationZealand Pharma A/S Interim report for Q (un-audited)
Company Announcement No. 12/2012 (un-audited) Net profit for the quarter of DKK 66 (EUR 9) million Important pipeline progress, and revenue from milestone payments of DKK 120 (EUR 16) million Cash and
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationJefferies Healthcare Conference June 6, 2018
Jefferies Healthcare Conference June 6, 2018 Forward-Looking Statements Some of the statements included in this presentation, particularly those regarding the commercialization and ongoing clinical development
More informationPATENCY-1 Top-Line Results
PATENCY-1 Top-Line Results December 13, 2016 2016 Proteon Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This presentation contains statements that are, or may be deemed to be,
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationOur future workforce. Flemming Dahl, Senior Vice President and Head of Quality, Novo Nordisk
Our future workforce Flemming Dahl, Senior Vice President and Head of Quality, Novo Nordisk ISPE Nordic 17. Nov. 2016 2 Who am I? Head of Quality in Novo Nordisk 48 years Danish Married 5 Children [7-19]
More informationInnovation In Ophthalmics
Innovation In Ophthalmics Ophthalmic Innovation Summit @ AAO 2018 October 25, 2018 Mark Iwicki Chairman & CEO, Kala Pharmaceuticals Disclaimers and Notices This presentation contains forward-looking statements
More informationOBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss
OBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss Forward looking statements Except for statements of historical fact, information
More informationDiagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015
Diagnostics for the early detection and prevention of colon cancer Fourth-Quarter 2014 Earnings Call February 24, 2015 Safe Harbor Statement Certain statements made in this presentation contain forward-looking
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended
More informationUCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth
Brussels (Belgium), February 018 7:00 (CET) regulated information UCB Full Year Report 017: UCB, with a strong year 017, is reinforcing a solid foundation for investing in future growth Positive growth
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationINVESTOR PRESENTATION JEFFERIES 2013 HEALTHCARE CONFERENCE. June 2013
INVESTOR PRESENTATION JEFFERIES 2013 HEALTHCARE CONFERENCE June 2013 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events
More informationTelekom Austria Group Results for the 1st Quarter May 27, 2003
Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those
More informationPresentation of ALK London, 24 May 2011 UBS GLOBAL SPECIALTY PHARMACEUTICALS CONFERENCE : LONDON : 24 MAY 2011
Presentation of ALK London, 24 May 2011 1 ALK pharma specialist - treatment, prevention and diagnosis of allergies World leader in allergy immunotherapy ~ 33% global market share Expanding Base Business
More information1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationCowen Healthcare Conference
Cowen Healthcare Conference Shire plc March 9, 2010 Michael Cola President, Specialty Pharmaceuticals Our purpose We enable people with life-altering conditions to lead better lives 1 THE SAFE HARBOR STATEMENT
More informationFor personal use only
Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for
More informationFinancial, social and environmental performance. Our focus is our strength
Financial, social and environmental performance Our focus is our strength Performance highlights 2008 2008 2007 Change Financial performance Sales total DKK million 45,553 41,831 9% Diabetes care DKK million
More informationTreatment of visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO):
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Treatment of visual impairment due to macular edema secondary to branch retinal
More informationChronic illness is a growing market for Novo Nordisk
Chronic illness is a growing market for Novo Nordisk Aslam Dalvi - Associate Portfolio Manager Denmark-based global healthcare company Novo Nordisk traces its origins to the first pioneers in insulin production
More informationColoplast A/S. Investor presentation 1H 2005/06
Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound
More informationCompany Overview February 26, 2019
Company Overview February 26, 2019 SAFE HARBOR Cautionary Note Regarding Forward-Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationInvestor Presentation. Q April 26, 2018
Investor Presentation Q3 2018 April 26, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private Securities
More informationNovartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention
Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.novartis.com MEDIA RELEASE COMMUNIQUE AUX MEDIAS MEDIENMITTEILUNG Novartis announces Phase III STRIVE data
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationLilly Diabetes: Pipeline Update
Lilly Diabetes: Pipeline Update June 16, 2014 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More informationFY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009
FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION August 3, 2009 Consolidated: Financial Summary Page 2 FY2009 1Q FY2008 4Q 09/4-6 09/1-3 Change FY2008 1Q 08/4-6 Change (Billion Yen) (A)
More informationInnovation In Ophthalmology
Innovation In Ophthalmology INVELTYS TM Approval August 2018 Disclaimers and Notices This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference
ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference Mick Farrell CEO January 8, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking
More informationEli Lilly and Company
Eli Lilly and Company Strategic Diabetes Alliance with Boehringer Ingelheim January 11 th, 2011 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's
More informationGalvus US NDA Approvable - Overview
Galvus US NDA Approvable - Overview Galvus NDA filed with FDA Jan 2006 PDUFA action date extended by 3 months until February 26th 2007 Significant new clinical data added to NDA - Approximately 1000 patient
More informationQ Investor Kit JANUARY-MARCH 2014
Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationKorean Airlines Q Results
Korean Airlines 2010 2Q Results 2010. 8. 13 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and
More informationMerrill Lynch conference. Matthew Emmens, CEO Shire plc September 20, 2007
Merrill Lynch conference Matthew Emmens, CEO Shire plc September 20, 2007 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical
More informationFY2007 Consolidated Financial Overview
FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking
More informationDesigning a Smoke-Free Future
Designing a Smoke-Free Future Morgan Stanley Global Consumer & Retail Conference New York, November 14, 2017 Jacek Olczak Chief Financial Officer Martin King President, Asia Region Forward-Looking and
More informationConsolidated: Financial Summary
FY2010 First Quarter Financial Results SUZUKI MOTOR CORPORATION 3 August 2010 Consolidated: Financial Summary Page2 FY2010 1Q FY2009 1Q (2010/4-6) (2009/4-6) Change Net sales 656.3 577.1 +79.2 +13.7% Operating
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More information